Filing Flows › Xilio Therapeutics (XLO) › Q3 2025
Xilio Therapeutics (XLO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Xilio Therapeutics (XLO) reported revenue of $19.1M for the third quarter 2025 (Q3 2025), +743% from a year earlier and +136% from the quarter before. Operating margin was -10.1%, net loss $16.3M (85.4% of revenue).
Xilio Therapeutics, Q3 2025: revenue $19.1M (+742% year over year), operating margin -10.1%, net loss $16.3M, operating cash flow −$17.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.1M | +136% | +743% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$16.3M | — | — |
| Operating cash flow | −$17.5M | — | — |
What changed
Revenue was $19.1M in Q3 2025, up 743% year over year and up 136% from the previous quarter.
Operating costs exceeded revenue by $1.9M, an operating margin of -10.1%. Total costs grew 23% against revenue growth of 743%. The fastest-growing cost line was Research & development (+33%). The quarter ended with a net loss of $16.3M, wider than the previous quarter's $15.8M loss. Net interest and other expense of $14.4M was the main reason.
Operating cash flow was −$17.5M. Non-cash charges added back $340K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $2.7M.
Questions
What was Xilio Therapeutics' revenue in the third quarter 2025?
Xilio Therapeutics (XLO) reported revenue of $19.1M for the third quarter 2025 (Q3 2025), +743% from a year earlier and +136% from the quarter before.
Was Xilio Therapeutics profitable in the third quarter 2025?
Operating loss was $1.9M (-10.1% of revenue) and net loss $16.3M.
Source: Xilio Therapeutics 10-Q on SEC EDGAR.